Compare VKTX & ITGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VKTX | ITGR |
|---|---|---|
| Founded | 2012 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.1B |
| IPO Year | 2014 | 2000 |
| Metric | VKTX | ITGR |
|---|---|---|
| Price | $38.86 | $93.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $95.86 | $91.14 |
| AVG Volume (30 Days) | ★ 3.0M | 424.4K |
| Earning Date | 04-29-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.48 |
| Revenue | N/A | ★ $1,853,637,000.00 |
| Revenue This Year | N/A | $1.69 |
| Revenue Next Year | N/A | $6.53 |
| P/E Ratio | ★ N/A | $191.56 |
| Revenue Growth | N/A | ★ 7.98 |
| 52 Week Low | $22.96 | $62.00 |
| 52 Week High | $43.15 | $120.41 |
| Indicator | VKTX | ITGR |
|---|---|---|
| Relative Strength Index (RSI) | 60.36 | 55.89 |
| Support Level | $29.10 | $82.58 |
| Resistance Level | $39.78 | $95.48 |
| Average True Range (ATR) | 2.72 | 2.60 |
| MACD | 0.39 | -0.09 |
| Stochastic Oscillator | 69.76 | 73.19 |
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns maximum of its revenue in the United States, and also has its presence in Ireland, Puerto Rico, Costa Rica, and Rest of the World.